香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣佈，近日，注射用HLX43（靶向PD-L1抗體 偶聯藥物）（「HLX43」）聯合HLX07（重組抗EGFR人源化單克隆抗體注射液） （「HLX07」）及漢斯狀® （斯魯利單抗注射液）（「漢斯狀®」）用於晚期實體瘤治 療的臨床試驗申請獲國家藥品監督管理局（「NMPA」）批准。本公司擬於條件 具備後於中國境內開展相關臨床試驗。 1 B. 關於HLX43、HLX07及漢斯狀® HLX43是由本公司利用許可引進的新型DNA拓撲異構酶I抑制劑小分子毒 素－肽鏈連接符與本公司自主研發的靶向PD-L1的抗體進行偶 ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，生物股份1月27日晚间发布公告称，内蒙古金宇生物控股有限公司持有金宇生物技术股份 有限公司股份约1.25亿股，占公司总股本的11.29%。本次股份质押后，其累计质押公司股份数量为3442 万股，占生物控股持有公司股份数量的27.43%。 ...

Core Viewpoint - The company, CanSino Biologics (06185), anticipates significant revenue growth and a turnaround in profitability by the end of 2025, driven by innovative product offerings and effective cost management [1] Financial Projections - The company expects to achieve operating revenue between RMB 1.04 billion and RMB 1.08 billion for the year ending December 31, 2025, representing an increase of RMB 194 million to RMB 234 million compared to the previous year, which translates to a year-on-year growth of 22.88% to 27.61% [1] - The projected net profit attributable to the owners of the parent company is expected to be between RMB 24.5 million and RMB 29 million, indicating a return to profitability compared to the previous year [1] - The expected net loss attributable to the owners of the parent company, after excluding non-recurring gains and losses, is projected to be between RMB 91 million and RMB 96 million [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization, with the first four-valent meningococcal vaccine, Manhaixin, showing sustained revenue growth [1] - The company has made significant progress in cost reduction and efficiency improvement, effectively managing various expenses, which has led to an increase in gross margin [1] - Overall profitability has significantly improved, achieving a positive net profit attributable to the owners of the parent company during the reporting period [1] Research and Funding - The rapid advancement of the company's R&D projects and international collaborations has resulted in increased government grants and international funding support, contributing to substantial non-recurring income during the reporting period [1]

Investment Rating - The report assigns a "Buy" rating for the company, Lepu Biopharma (2157.HK), marking its first coverage [1]. Core Insights - The company is entering a harvest period for new drug approvals, having established a comprehensive pipeline in oncology that includes immunotherapy, ADC (Antibody-Drug Conjugate) targeted therapy, and oncolytic virus drugs. The company has multiple ADC drugs and other therapies in clinical stages, with expectations for new drug approvals in the next 3-5 years [3][10]. - The ADC pipeline is characterized by unique features and competitive advantages in various indications, with MRG003 (EGFR ADC) already approved for NPC (nasopharyngeal carcinoma) in China and showing promising results in other indications [4][30]. - The introduction of oncolytic virus therapy CG0070 has shown potential in the bladder cancer market, with successful regulatory progress in the U.S. and ongoing clinical trials in China [5][30]. - Financially, the company has achieved its first profit and positive operating cash flow in the first half of 2025, with steady revenue growth driven by business development and sales [25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, with a pipeline that includes immunotherapy, ADCs, and oncolytic virus therapies. It has developed a robust ADC technology platform and has multiple products in various stages of clinical development [11][10]. - The pipeline includes 6 ADC drugs and 1 oncolytic virus therapy, with several candidates in pivotal clinical stages, indicating a well-structured development strategy [14][10]. Unique Features of ADCs - MRG003 has been approved for NPC and is in advanced trials for HNSCC (head and neck squamous cell carcinoma) and NSCLC (non-small cell lung cancer), showcasing its broad applicability and competitive edge [30][4]. - Other ADCs in development, such as MRG004A for pancreatic cancer and MRG006A for liver cancer, are also progressing well, with MRG004A entering pivotal trials [30][6]. Financial Performance and Projections - The company reported revenues of 4.66 billion yuan in the first half of 2025, a significant increase from 1.33 billion yuan in the same period of 2024. The net profit for the same period was 290 million yuan, marking a turnaround from a loss of 197 million yuan in the previous year [25][30]. - Revenue projections for 2025, 2026, and 2027 are estimated at 8.8 billion yuan, 10.2 billion yuan, and 14.9 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [30].

格隆汇1月27日丨康希诺生物(06185.HK)发布公告，根据中国企业会计准则，预计截至2025年12月31日 止年度集团实现营业收入人民币10.40亿元到人民币10.80亿元，与上年同期相比，将增加人民币1.937亿 元到人民币2.337亿元，同比增长22.88%到27.61%。预计截至2025年12月31日止年度实现归属于母公司 所有者的净利润为人民币2450万元到人民币2900万元，与上年同期相比，将实现扭亏为盈。 报告期内，集团持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗 曼海欣®收入保持持续增长。同时，集团深入推进降本增效，各项费用得到有效管控；产销协同进一步 优化，毛利率亦有所提升。整体盈利能力显着提升，成功于本报告期实现归属于母公司所有者的净利润 为正。 ...

Core Viewpoint - The company expects revenue for 2025 to be between 340 million to 360 million yuan, an increase from 204 million yuan in the same period last year, while net profit attributable to shareholders is projected to be a loss of 30 million to 40 million yuan, improving from a loss of 110 million yuan in the previous year, indicating a year-on-year growth of 63.63% to 72.73% in net profit [1] Revenue Summary - The revenue growth is primarily driven by a significant increase in sales from the wholly-owned subsidiary, Chenwei Ecological Park [1] - The expected revenue for 2025 is projected to be between 340 million to 360 million yuan, compared to 204 million yuan in the previous year [1] Profit Summary - The improvement in net profit is attributed to a reduction in asset impairment losses and operating expenses, as well as effective cost control measures at the controlling subsidiary, Beijing Sihuan Biological Pharmaceutical [1] - The projected net loss for 2025 is between 30 million to 40 million yuan, a notable improvement from the previous year's loss of 110 million yuan [1] Risk Warning - Due to the negative net profit in 2024 and revenue below 300 million yuan, the company's stock will be subject to delisting risk warning starting April 30, 2025, and may face termination of listing if financial indicators meet specified conditions [1]

Core Viewpoint - The company is facing a delisting risk warning starting from April 30, 2025, due to potential conditions outlined in the stock listing rules, which could lead to termination of its stock listing after the 2025 annual report is disclosed [1] Financial Performance - The company has announced an earnings forecast for 2025, expecting a non-recurring net profit of between -46 million yuan and -33 million yuan, with operating revenue projected to be between 330 million yuan and 350 million yuan, which is unaudited [1] - The company will provide risk warnings every ten trading days until the annual report is disclosed [1]

Core Viewpoint - The company, CanSino Biologics (06185), anticipates significant revenue growth and a turnaround in profitability by the end of 2025, driven by innovative product offerings and effective cost management [1] Financial Projections - The company expects to achieve an operating revenue of RMB 1.04 billion to RMB 1.08 billion for the fiscal year ending December 31, 2025, representing an increase of RMB 194 million to RMB 234 million compared to the previous year, which translates to a year-on-year growth of 22.88% to 27.61% [1] - The projected net profit attributable to the owners of the parent company is expected to be between RMB 24.5 million and RMB 29 million, indicating a turnaround from a loss to profitability compared to the previous year [1] - The company anticipates a net loss attributable to the owners of the parent company, excluding non-recurring gains and losses, to be between RMB 91 million and RMB 96 million [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization, with the revenue from its first quadrivalent meningococcal conjugate vaccine, Manhaixin, showing sustained growth [1] - The company has made significant progress in cost reduction and efficiency improvement, effectively managing various expenses, which has led to an enhancement in gross margin [1] - The overall profitability has significantly improved, achieving a positive net profit attributable to the owners of the parent company during the reporting period [1] Research and Funding - The rapid advancement of the company's R&D projects and international collaborations has resulted in increased government grants and international funding support, contributing to substantial non-recurring gains during the reporting period [1]

格隆汇1月27日丨康希诺生物(06185.HK)发布公告，根据中国企业会计准则，预计截至2025年12月31日 止年度集团实现营业收入人民币10.40亿元到人民币10.80亿元，与上年同期相比，将增加人民币1.937亿 元到人民币2.337亿元，同比增长22.88%到27.61%。预计截至2025年12月31日止年度实现归属于母公司 所有者的净利润为人民币2450万元到人民币2900万元，与上年同期相比，将实现扭亏为盈。 报告期内，集团持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗 曼海欣®收入保持持续增长。同时，集团深入推进降本增效，各项费用得到有效管控；产销协同进一步 优化，毛利率亦有所提升。整体盈利能力显着提升，成功于本报告期实现归属于母公司所有者的净利润 为正。 ...

每经AI快讯，康希诺1月27日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润为 2450万元~2900万元，与上年同期相比，将实现扭亏为盈。业绩变动主要原因是，主营业务影响。报告 期内，公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗曼海 欣®收入保持持续增长。同时，公司深入推进降本增效，各项费用得到有效管控；产销协同进一步优 化，毛利率亦有所提升。整体盈利能力显著提升，成功于报告期实现归属于母公司所有者的净利润为 正。非经常性损益的影响。报告期内，随着公司研发项目的快速推进及国际合作的开展，公司获得了更 多政府专项补助及国际专项资金的支持，故于报告期产生较大金额的非经常性收益。 （记者 王瀚黎） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...